Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study

Lancet Oncology

Volumn 8, Issue 7, 2007, Pages 587-594

  Nilsson, Sten ^a,b   Franzén, Lars ^c   Parker, Christopher ^d   Tyrrell, Christopher ^e   Blom, René ^f   Tennvall, Jan ^g   Lennernäs, Bo ^h   Petersson, Ulf ⁱ   Johannessen, Dag C ^j   Sokal, Michael ^k   Pigott, Katharine ^l   Yachnin, Jeffrey ^a   Garkavij, Michael ^g   Strang, Peter ^b   Harmenberg, Johan ^b,m   Bolstad, Bjørg ^m   Bruland, Øyvind S ⁿ  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Länssjukhuset Sundsvall Härnösand   (Sweden)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e Plymouth General Hospital   (United Kingdom)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ Centrallasarettet i Västerås   (Sweden)

^j HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^k NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^l ROYAL FREE HOSPITAL   (United Kingdom)

^m Algeta ASA   (Norway)

ⁿ UNIVERSITY OF OSLO   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ALPHARADIN; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; CYTOTOXIC AGENT; HORMONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; RADIUM 223; UNCLASSIFIED DRUG;

ADRENAL DISEASE; ADULT; AGED; ARTICLE; ATAXIA; BLOOD TOXICITY; BONE METASTASIS; BONE PAIN; CACHEXIA; CANCER RESISTANCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DRUG FEVER; DRUG TARGETING; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FALLING; GRAM NEGATIVE INFECTION; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPOCALCEMIA; INTESTINE OBSTRUCTION; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; NEUTROPHIL; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; SPINAL CORD COMPRESSION; SUBDURAL HEMATOMA; THORAX PAIN; THROMBOCYTE; TUMOR; VOMITING; WILCOXON SIGNED RANKS TEST;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE NEOPLASMS; DOUBLE-BLIND METHOD; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIUM; SURVIVAL RATE;

EID: 34347244905     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70147-X     Document Type: Article

References (15)

1. Saad F., Gleason D., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879-882
2. Finlay I., Mason M., and Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 6 (2005) 392-400
3. Lewington V. Bone-seeking radionuclides for therapy. J Nucl Med 46 suppl 1 (2005) 38-47S
4. 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med 44 (2003) 252-259
5. Henriksen G., Breistol K., Bruland O., et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res 62 (2002) 3120-3125
6. Nilsson S., Larsen R., Fossa S., et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 11 (2005) 4451-4459
7. Bubley G., Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17 (1999) 3461-3467
8. Klepstad P., Loge J., Borchgrevink P., et al. The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients. J Pain Symptom Manage 24 (2002) 517-525
9. Soloway M., Hardeman S., Hickey D., et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61 (1988) 195-202
10. Porter A., McEwan A., Powe J., et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25 (1993) 805-813
11. 223Ra: adjuvant or alternative to conventional modalities?. Clin Cancer Res 12 (2006) 6250-657s
12. Tannock I., de Wit R., Berry W., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
13. Saad F., Gleason D., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (2002) 1458-1468
14. Tu S., Millikan R., Mengistu B., et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357 (2001) 336-341
15. Palmedo H., Manka-Waluch A., Albers P., et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 21 (2003) 2869-2875